Drug Type Antibody fusion proteins |
Synonyms HLA-E-targeted TCR bispecific molecule |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HLA-E inhibitors(major histocompatibility complex, class I, E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tuberculosis | Preclinical | GB | 01 May 2024 |